Travatan, Travoprost Newswire

Travatan, Travoprost Newswire

Comprehensive Real-Time News Feed for Travatan, Travoprost (generic).

Results 1 - 20 of 48 in Travatan, Travoprost (generic)

  1. IDE Pivotal Trial Results for Glaukos' iStent inject Show Significant ...Read the original story

    Saturday Apr 14 | Customer Interaction Solutions

    IDE Pivotal Trial Results for Glaukos' iStent inject Show Significant Reductions in Unmedicated IOP in Glaucoma Subjects Undergoing Cataract Surgery Glaukos Corporation , an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced that two-year U.S. Investigational Device Exemption pivotal trial data showed that its iStent inject Trabecular Micro-Bypass System achieved a statistically significant reduction in unmedicated diurnal intraocular pressure in patients undergoing cataract surgery.

    Comment?

  2. International Study Shows Long-Term Titrated IOP Control with 1, 2 or ...Read the original story

    Feb 27, 2018 | Customer Interaction Solutions

    International Study Shows Long-Term Titrated IOP Control with 1, 2 or 3 Glaukos iStent Trabecular Micro-Bypass Stents in Open-Angle Glaucoma Patients Glaukos Corporation , an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced that, according to a study published in Clinical Ophthalmology , implantation of one, two or three iStent Trabecular Micro-Bypass Stents achieved mean unmedicated intraocular pressure reductions of 30%, 37% and 43%, respectively, at 36 months postoperative.

    Comment?

  3. Ocular Therapeutix (OCUL) & Cryolife (CRY) Head to Head AnalysisRead the original story w/Photo

    Feb 11, 2018 | Daily Political

    Ocular Therapeutix and Cryolife are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability and analyst recommendations. Ocular Therapeutix presently has a consensus target price of $20.67, suggesting a potential upside of 310.87%.

    Comment?

  4. Quotidian Technical Highlights on Selected Medical Supplies Stocks -- ...Read the original story w/Photo

    Feb 7, 2018 | PR Newswire

    WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on ELGX, GKOS, and MZOR, which can be accessed for free by signing up to www.wallstequities.com/registration .

    Comment?

  5. Ocular Therapeutix (OCUL) & Cryolife (CRY) Financial AnalysisRead the original story w/Photo

    Feb 3, 2018 | AmericanBankingNews.com

    Ocular Therapeutix and Cryolife are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, risk, valuation, institutional ownership, earnings, analyst recommendations and profitability. 53.1% of Ocular Therapeutix shares are owned by institutional investors.

    Comment?

  6. Head to Head Review: Ocular TherapeutixRead the original story w/Photo

    Jan 18, 2018 | Daily Political

    Ocular Therapeutix and Lombard Medical are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, dividends, profitability, valuation and risk. Lombard Medical has higher revenue and earnings than Ocular Therapeutix.

    Comment?

  7. Critical Contrast: Ocular TherapeutixRead the original story w/Photo

    Jan 12, 2018 | IntersportsWire

    Ocular Therapeutix and Alliqua Biomedical are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, valuation, risk and dividends. Alliqua Biomedical has higher revenue and earnings than Ocular Therapeutix.

    Comment?

  8. Glaukos Corporation's iDosea Travoprost Achieves Sustained IOP...Read the original story

    Jan 10, 2018 | Customer Interaction Solutions

    Glaukos Corporation , an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced that its Travoprost Intraocular Implant with the iDose delivery system continued to provide sustained reduction in intraocular pressure in a 12-month interim cohort of patients in its U.S. Investigational New Drug Phase II clinical trial. Implanted during a micro-invasive procedure, the iDose Travoprost is filled with a special formulation of travoprost, a prostaglandin analog used to reduce IOP, and designed to continuously elute therapeutic levels of the medication from within the eye for extended periods of time.

    Comment?

  9. Head to Head Survey: Ocular TherapeutixRead the original story w/Photo

    Jan 9, 2018 | AmericanBankingNews.com

    Ocular Therapeutix and Alliqua Biomedical are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, institutional ownership, valuation, dividends, analyst recommendations, earnings and profitability. Alliqua Biomedical has higher revenue and earnings than Ocular Therapeutix.

    Comment?

  10. Glaucoma Pharmaceuticals Market to Remain Lucrative During 2019Read the original story w/Photo

    Dec 27, 2017 | SBWire

    Glaucoma is caused due to rise in the intraocular pressure, if persists may lead to permanent eye damage.This increased pressure damages the optic nerve which transmits message to the brain High pressure is built due to the blockage of the trabecular meshwork which results in the accumulation of aqueous humor. Depending on the size of trabecular meshwork blockage, glaucoma can be categorized as open angle and narrow closure glaucoma.

    Comment?

  11. Comparing Ocular TherapeutixRead the original story w/Photo

    Dec 26, 2017 | Daily Political

    Ocular Therapeutix and West Pharmaceutical Services are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, earnings, institutional ownership, risk, analyst recommendations and valuation. 52.9% of Ocular Therapeutix shares are held by institutional investors.

    Comment?

  12. Analyzing Ocular TherapeutixRead the original story w/Photo

    Dec 25, 2017 | AmericanBankingNews.com

    Ocular Therapeutix and Hill-Rom are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk. Ocular Therapeutix has a beta of 1.31, indicating that its share price is 31% more volatile than the S&P 500.

    Comment?

  13. Head to Head Comparison: West Pharmaceutical ServicesRead the original story w/Photo

    Dec 23, 2017 | IntersportsWire

    West Pharmaceutical Services and Ocular Therapeutix are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, risk and valuation. 93.3% of West Pharmaceutical Services shares are held by institutional investors.

    Comment?

  14. Ocular Therapeutixa Provides Legal UpdateRead the original story

    Dec 22, 2017 | Customer Interaction Solutions

    Ocular Therapeutix, Inc. , a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye, today provided an update on legal matters related to the Company's manufacture of its product candidate, DEXTENZA 0.4mg. "), including its most recent Quarterly Report on Form 10-Q filed on November 7, 2017, the Company and certain of its current and former executive officers and board members were named as defendants in a derivative lawsuit filed in the Superior Court of Suffolk County of the Commonwealth of Massachusetts, captioned Angel Madera v.

    Comment?

  15. The Pros and Cons of PreservativesRead the original story

    Dec 12, 2017 | Review of Ophthalmology

    As you know , preservatives are a mixed blessing. The Food and Drug Administration requires that multidose bottles of medications include a preservative to kill bacteria and fungi that may contaminate the fluid in the bottle; as a result, for several decades our medications have contained preservatives specifically designed to keep the medications sterile during patient use and the life cycle of the bottle.

    Comment?

  16. Identifying Patients at Risk for NonadherenceRead the original story w/Photo

    Dec 11, 2017 | Review of Ophthalmology

    Because improving patient compliance requires time and effort, it makes sense to focus on those most likely to miss doses. As every ophthalmologist knows, medications - especially glaucoma medications - are worth-less if the patient doesn't use them.

    Comment?

  17. Financial Contrast: Ocular TherapeutixRead the original story w/Photo

    Dec 8, 2017 | IntersportsWire

    Ocular Therapeutix and Capnia are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, profitability, dividends and institutional ownership. Ocular Therapeutix has a beta of 1.32, indicating that its share price is 32% more volatile than the S&P 500.

    Comment?

  18. Comparing Ocular TherapeutixRead the original story w/Photo

    Dec 2, 2017 | Daily Political

    Ocular Therapeutix and C.R. Bard are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, analyst recommendations, profitability, earnings and risk. Ocular Therapeutix presently has a consensus price target of $20.67, indicating a potential upside of 414.10%.

    Comment?

  19. Ocular Therapeutix (OCUL) and Its Peers Head to Head AnalysisRead the original story w/Photo

    Nov 15, 2017 | The Breeze

    Ocular Therapeutix is one of 81 public companies in the "Medical Equipment, Supplies & Distribution" industry, but how does it weigh in compared to its competitors? We will compare Ocular Therapeutix to similar companies based on the strength of its institutional ownership, profitability, earnings, risk, analyst recommendations, valuation and dividends. 52.4% of Ocular Therapeutix shares are held by institutional investors.

    Comment?

  20. Critical Contrast: Ocular Therapeutix (OCUL) & Its PeersRead the original story w/Photo

    Nov 8, 2017 | AmericanBankingNews.com

    Ocular Therapeutix is one of 87 publicly-traded companies in the "Medical Equipment, Supplies & Distribution" industry, but how does it contrast to its competitors? We will compare Ocular Therapeutix to related businesses based on the strength of its valuation, institutional ownership, risk, profitability, dividends, analyst recommendations and earnings. 53.1% of Ocular Therapeutix shares are held by institutional investors.

    Comment?